Sanofi ($SNYNF) announced an update on their ongoing clinical study. Study Overview Sanofi has completed an observational study titled “Cognitive ...

EAST HANOVER, N.J., Oct. 18, 2017 /PRNewswire/ -- Novartis today announced long-term study results supporting the positive safety and efficacy of Promacta (eltrombopag) in adults with ...

Findings showed 23% of patients treated with rilzabrutinib achieved durable platelet response compared with none of the patients receiving placebo. The Food and Drug Administration (FDA) has approved ...

The clinical takeaways in immune thrombocytopenia (ITP) from the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition include the relative merits of advanced therapies, efficacy of ...

Sanofi’s Wayrilz, the first BTK inhibitor to treat immune thrombocytopenia gets European approval: Paris Saturday, December 27, 2025, 12:00 Hrs [IST] Sanofi, an R&D driven, AI-p ...

Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopeniaNovel treatment targets BTK through multi-immune ...

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called ...

Results of a phase 3 study presented Sunday found efgartigimod allowed a third of patients with immune thrombocytopenia (ITP) to quickly achieve platelet levels that signal an ability to avoid sudden ...

Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia (ITP) by 45%, according to data ...

An expert discusses the importance of patient education and personalized, flexible treatment planning in managing chronic immune thrombocytopenic purpura (ITP), highlighting proactive strategies like ...

Children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy show significantly improved platelet responses and other outcomes compared with the standard ...